“Asenapine is a well-established treatment option and delivering it transdermally with SECUADO provides a non-intrusive approach and visual confirmation of adherence,” said Leslie Citrome, M.D., M.P.H ...

The antipsychotic "patch" effectively reduced hostility among patients with schizophrenia, a researcher reported. In a post-hoc analysis of a phase III trial, once-daily asenapine transdermal system ...

– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated ...

Methods: The algorithm used a single payer’s Medicaid medical and pharmacy claims (August 1, 2009, to July 31, 2014) for patients with schizophrenia (N = 12,353) to predict those at high risk for ...

There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...

Patients and prescribers alike are familiar with the vast array of psychiatric medicines available to treat mental illnesses. They are often less aware that certain psychotropics can be delivered via ...

Patients and prescribers alike are familiar with the vast array of psychiatric medicines available to treat mental illnesses. They are often less aware that certain psychotropics can be delivered via ...